University Hospital of Cologne, Cologne, Germany
[email protected]
Dr. Fätkenheuer reports being a member of and receiving funding from the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), being the principal investigator of the Strategic Timing of Antiretroviral Treatment (START) trial for Germany, and receiving a grant (01KG0915) from the German Federal Ministry of Education and Research (BMBF). Drs. Lehmann, Wyen, and Fätkenheuer report receiving a grant (01KI1017) from the BMBF. No other potential conflict of interest relevant to this letter was reported.
